News & Updates

Show Multimedia Only
Seladelpar safe, effective for primary biliary cholangitis

Seladelpar safe, effective for primary biliary cholangitis

10 Apr 2022

In patients with primary biliary cholangitis, the use of seladelpar, a selective peroxisome proliferator-activated receptor-delta agonist, safely improves biochemical markers of cholestasis and inflammation, reports a new study.

Seladelpar safe, effective for primary biliary cholangitis

10 Apr 2022
Hepatitis B virus treatment rates still low among eligible patients

Hepatitis B virus treatment rates still low among eligible patients

10 Apr 2022
Aspirin-statin combo lowers hepatocellular carcinoma incidence

Aspirin-statin combo lowers hepatocellular carcinoma incidence

09 Apr 2022

Daily use of aspirin reduces the risk of incident hepatocellular carcinoma (HCC), while the combination of daily aspirin use and statin results in a lower incidence of HCC, which suggests a beneficial interaction, according to a study. In addition, no excess oesophageal variceal haemorrhage (VH) is seen among daily aspirin users compared with nonusers.

Aspirin-statin combo lowers hepatocellular carcinoma incidence

09 Apr 2022